Equillium

Equillium FCF/Debt

The Free Cash Flow to Debt Ratio of Equillium (EQ) as of Oct 22, 2026 is -6,279.34 %. In the previous year, Free Cash Flow to Debt Ratio was -100.69 % — a change of 6,136.14% (lower).

FCF/Debt

-6,279.34 %

YoY

6,136.14%

Last updated:

Free Cash Flow to Debt Ratio of Equillium is 2025 -6,279.34 % . Free Cash Flow to Debt Ratio of Equillium was 2024 -100.69 % . It decreases by 6,136.14% lower compared to the previous year.

The Equillium FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2017
-8.24 USD
Jan 1, 2019
-237.84 USD
Jan 1, 2020
-249.76 USD
Jan 1, 2021
-315.70 USD
Jan 1, 2022
-100.69 USD
Jan 1, 2025
-6,279.34 USD
The Equillium FCF/Debt history
YEARFCF/DebtYoY
-6,279.34 %+6,136.14%
-100.69 %-68.10%
-315.70 %+26.40%
-249.76 %+5.01%
-237.84 %+2,785.31%
-8.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Equillium Stock analysis

What does Equillium do? Equillium Inc is an emerging biotechnology company specializing in the research and development of therapies for the treatment of inflammatory and autoimmune diseases. The company was founded in 2017 by a group of experienced biotech entrepreneurs who aim to develop innovative and effective treatment methods to improve patients' quality of life. Equillium's business model focuses on the discovery and development of new therapies based on the modulation of the CD6 signaling pathway, a central regulator of the immune system. Equillium's technology aims to modulate the immune system to suppress an inflammatory response associated with autoimmune and other inflammatory diseases. The company collaborates closely with leading university research laboratories and experts in the field to develop effective therapies. Equillium targets a wide range of disease areas, including autoimmune diseases such as lupus, psoriasis, and Crohn's disease. The company has also developed a program to treat COVID-19, aiming to reduce the immune-mediated inflammatory response associated with severe cases of COVID-19. Equillium's product portfolio includes EQ001, a monoclonal antibody used for the treatment of lupus and other autoimmune diseases. EQ001 blocks the CD6 signaling pathway, thereby reducing inflammatory responses that attack healthy tissues in the body. The company is also working on developing a novel platform technology to explore additional therapy options based on the CD6 signaling pathway. Equillium has a strong funding base and is supported by some of the most renowned biotech investors. The company has a comprehensive pipeline of potential therapies that are intended to address a variety of indications in the future. Overall, Equillium's advanced biotechnological research and development have contributed to the discovery of new and effective ways to treat inflammatory and autoimmune diseases. The company is well-positioned to expand in this area of medicine and improve therapy options for patients worldwide. Equillium is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Equillium stock

Free Cash Flow to Debt Ratio of Equillium is -6,279.34 % in 2025.

Free Cash Flow to Debt Ratio of Equillium changed from -100.69 % to -6,279.34 %, representing a 6,136.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Equillium since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Equillium with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Equillium

All Key Metrics — Equillium